Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | KDM1A | O60341 | 8/20 | 0.63 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.54 |
| ▸ | MAOA | P21397 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | TLR2 | O60603 | 2/20 | 0.52 |
| ▸ | TLR1 | Q15399 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31018747 | 1.00 | SMN1; SMN2 (0.69) | SMN1; SMN2NPSR1KDM1ACNR1EPHX2 | |
| SCHEMBL20696269 | 1.00 | SMN1; SMN2 (0.69) | SMN1; SMN2NPSR1KDM1ACNR1EPHX2 | |
| SCHEMBL8294081 | 1.00 | SMN1; SMN2 (0.69) | SMN1; SMN2NPSR1KDM1ACNR1EPHX2 | |
| SCHEMBL6153775 | 0.85 | SMN1; SMN2 (0.73) | SMN1; SMN2NPSR1KDM1ACNR1EPHX2 | |
| SCHEMBL7980208 | 0.85 | SMN1; SMN2 (0.73) | SMN1; SMN2NPSR1KDM1ACNR1EPHX2 | |
| SCHEMBL3457343 | 0.85 | SMN1; SMN2 (0.73) | SMN1; SMN2NPSR1KDM1ACNR1EPHX2 | |
| SCHEMBL6154005 | 0.85 | SMN1; SMN2 (0.73) | SMN1; SMN2NPSR1KDM1ACNR1EPHX2 | |
| SCHEMBL25021708 | 0.81 | SMN1; SMN2 (1.00) | SMN1; SMN2NPSR1KDM1ACNR1EPHX2 | |
| SCHEMBL13794162 | 0.81 | SMN1; SMN2 (1.00) | SMN1; SMN2NPSR1KDM1ACNR1EPHX2 | |
| SCHEMBL22293284 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2NPSR1KDM1ACNR1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | SMN1; SMN2 1509/4885NPSR1 62/4885KDM1A 913/4885 |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | SMN1; SMN2 1477/4885NPSR1 67/4885KDM1A 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.